Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Jan A. Burger(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Maro Ohanian(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Mariela Sivina(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Lynette Alexander-Williams(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Mathew Thomas(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Ekaterina Kim(The University of Texas MD Anderson Cancer Center), Graciela Nogueras González(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine)
Blood
December 7, 2017
10.1182/blood.v130.suppl_1.427.427
Cited by 15

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k